文献速递血栓与止血MDS 与骨髓增殖性肿瘤

JAK-STAT抑制可减少内皮促血栓激活及白细胞-内皮促黏附相互作用

JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte-endothelial proadhesive interactions.
PubMed 文献 · J Thromb Haemost · 2023-02-02

本研究探讨JAK-STAT抑制剂芦可替尼和fedratinib在内皮细胞中的抗炎与抗血栓作用。体外实验显示两者减少内皮磷酸化STAT1/STAT3信号、核内磷酸化NK-κB和c-Jun定位,并降低P-选择素、血管性血友病因子、IL-6、组织因子及尿激酶型纤溶酶原激活物表达与活性。内皮化微流控灌注全血实验表明,内皮经JAK-STAT抑制剂处理可阻止健康对照及JAK2V617F阳性骨髓增殖性肿瘤白细胞的滚动。

要点

  • 芦可替尼和fedratinib均减少内皮细胞磷酸化STAT1和STAT3信号。
  • JAK-STAT抑制降低内皮P-选择素、血管性血友病因子、IL-6、组织因子和uPA表达与活性。
  • 内皮经JAK-STAT抑制剂处理可阻止健康对照和JAK2V617F阳性MPN白细胞的滚动。

核心结论

  • JAK-STAT抑制剂可减少关键促血栓通路的上调,并阻止白细胞-内皮黏附的增加。

研究设计与样本

  • 实验研究:采用免疫印迹、免疫荧光、qRT-PCR和功能凝血试验评估内皮激活。
  • 使用内皮化微流控装置灌注正常及JAK2V617F阳性个体的全血以评估细胞黏附。

主要发现

  • 芦可替尼和fedratinib均减少内皮细胞磷酸化STAT1和STAT3信号,并减弱核内磷酸化NK-κB和磷酸化c-Jun定位。
  • JAK-STAT抑制限制促黏附和促凝的P-选择素与血管性血友病因子分泌以及促炎IL-6分泌。
  • JAK-STAT抑制降低内皮组织因子和尿激酶型纤溶酶原激活物的表达与活性。
  • 内皮经JAK-STAT抑制剂处理可阻止健康对照和JAK2V617F阳性MPN白细胞的滚动。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vascular activation is characterized by increased proinflammatory, pro thrombotic, and proadhesive signaling. Several chronic and acute conditions, including Bcr-abl-negative myeloproliferative neoplasms (MPNs), graft-vs-host disease, and COVID-19 have been noted to have increased activation of the janus kinase (JAK)-signal transducer and downstream activator of transcription (STAT) pathways. Two notable inhibitors of the JAK-STAT pathway are ruxolitinib (JAK1/2 inhibitor) and fedratinib (JAK2 inhibitor), which are currently used to treat MPN patients. However, in some conditions, it has been noted that JAK inhibitors can increase the risk of thromboembolic complications. OBJECTIVES: We sought to define the anti-inflammatory and antithrombotic effects of JAK-STAT inhibitors in vascular endothelial cells. METHODS: We assessed endothelial activation in the presence or absence of ruxolitinib or fedratinib by using immunoblots, immunofluorescence, qRT-PCR, and function coagulation assays. Finally, we used endothelialized microfluidics perfused with blood from normal and JAK2V617F+ individuals to evaluate whether ruxolitinib and fedratinib changed cell adhesion. RESULTS: We found that both ruxolitinib and fedratinib reduced endothelial cell phospho-STAT1 and STAT3 signaling and attenuated nuclear phospho-NK-κB and phospho-c-Jun localization. JAK-STAT inhibition also limited secretion of proadhesive and procoagulant P-selectin and von Willebrand factor and proinflammatory IL-6. Likewise, we found that JAK-STAT inhibition reduced endothelial tissue factor and urokinase plasminogen activator expression and activity. CONCLUSIONS: By using endothelialized microfluidics perfused with whole blood samples, we demonstrated that endothelial treatment with JAK-STAT inhibitors prevented rolling of both healthy control and JAK2V617F MPN leukocytes. Together, these findings demonstrate that JAK-STAT inhibitors reduce the upregulation of critical prothrombotic pathways and prevent increased leukocyte-endothelial adhesion.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Beckman JD, DaSilva A, Aronovich E, et al. JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte-endothelial proadhesive interactions. J Thromb Haemost. 2023. PMID: 36738826. doi:10.1016/j.jtha.2023.01.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。